

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Effect of regulating gut microbiota using probiotics on brain activity: protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037582
Article Type:	Protocol
Date Submitted by the Author:	08-Feb-2020
Complete List of Authors:	Liu, Lu; Chengdu University of Traditional Chinese Medicine, Ni, Xixiu Tian, Tian Li, Xiao; Chengdu University of TCM, Acupuncture and Tuina School Li, Fengmei Sun, Mingsheng Chen, Jiao; Chengdu University of Traditional Chinese Medicine Zhou, SiYuan; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina, Zhao, Ling; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina
Keywords:	Microbiology < BASIC SCIENCES, Neurobiology < BASIC SCIENCES, Neuropathology < NEUROLOGY, Microbiology < PATHOLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, Head & neck imaging < RADIOLOGY & IMAGING

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title Page****Title**

Effect of regulating gut microbiota using probiotics on brain activity: protocol for a systematic review

**Authors**

Lu Liu, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; [liulu@stu.cdutcm.edu.cn](mailto:liulu@stu.cdutcm.edu.cn)

Xixiu Ni, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; [nixixiu@stu.cdutcm.edu.cn](mailto:nixixiu@stu.cdutcm.edu.cn)

Tian Tian, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; [tiantian@stu.cdutcm.edu.cn](mailto:tiantian@stu.cdutcm.edu.cn)

Xiao Li, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; [1039061367@qq.com](mailto:1039061367@qq.com)

Fengmei Li, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; [lifengmei@stu.cdutcm.edu.cn](mailto:lifengmei@stu.cdutcm.edu.cn)

Mingsheng Sun, PhD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; [sunmingsheng@stu.cdutcm.edu.cn](mailto:sunmingsheng@stu.cdutcm.edu.cn)

Jiao Chen, PhD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan [610075, China; chenjiao@cdutcm.edu.cn](mailto:chenjiao@cdutcm.edu.cn)

Siyuan Zhou, PhD: Acupuncture and Tuina School, Chengdu University of

1  
2  
3  
4 Traditional Chinese Medicine, Chengdu, Sichuan 610075,China;zsy@cdutcm.  
5  
6 edu.cn  
7  
8

9  
10 Ling Zhao, PhD: Acupuncture and Tuina School, Chengdu University of Traditional  
11  
12 Chinese Medicine, No.37 Shier Qiao Road, Chengdu, Sichuan 610075, China;  
13  
14 Tel:+8602887687008; [zhaoling@cdutcm.edu.cn](mailto:zhaoling@cdutcm.edu.cn); **(the corresponding author)**  
15  
16

### 17 18 **Author's Contributions**

19  
20  
21 LL developed the search strategy, TT and XL will search the databases and screen the  
22  
23 eligibility of the retrieved studies. FL and XN will extract information from the  
24  
25 eligible studies and prepare the information for data analysis. JC, MS and SZ will  
26  
27 perform the data analysis. LL and LZ wrote the first draft of the protocol. In practice,  
28  
29 LZ will monitor each procedure of the review and is responsible for quality control.  
30  
31 All authors read the article and approved it for publication. All authors read and  
32  
33 approved the final manuscript and order of authorship.  
34  
35

### 36 37 **Conflict of Interest Disclosures**

38  
39 None reported.  
40  
41

### 42 43 **Word Count**

44  
45  
46 2391 words.  
47  
48

### 49 50 **Key Words**

51  
52  
53 Probiotics, gut microbiota, brain activity, fMRI  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# Effect of regulating gut microbiota using probiotics on brain activity: protocol for a systematic review

Lu Liu, Xixiu Ni, Tian Tian, Xiao Li, Fengmei Li, Mingsheng Sun, Jiao Chen, Siyuan Zhou, Ling Zhao

Acupuncture and Tuina School, Chengdu University of TCM, Chengdu, Sichuan, China

## Authors:

Lu Liu, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; liulu@stu.cdutcm.edu.cn

Xixiu Ni, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; nixixiu@stu.cdutcm.edu.cn

Tian Tian, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; tiantian@stu.cdutcm.edu.cn

Xiao Li, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; 1039061367@qq.com

Fengmei Li, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; lifengmei@stu.cdutcm.edu.cn

Mingsheng Sun, PhD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; sunmingsheng

@stu.cdutcm.edu.cn

Jiao Chen, PhD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; chenjiao@cdutcm.edu.cn

Siyuan Zhou, PhD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; zsy@cdutcm.

edu.cn

Ling Zhao, PhD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, No.37 Shier Qiao Road, Chengdu, Sichuan 610075, China; Tel:+8602887687008; zhaoling@cducm.edu.cn; (the corresponding author)

### **Word Count:**

2,391 words

### **Key Words:**

probiotics, gut microbiota, brain activity, fMRI

### **Abstract**

**Introduction** There is a growing number of randomized controlled trials (RCTs) that focus on brain activity changes detected by fMRI and gut microbiota composition changes after using probiotics. However, the effect of probiotics on brain activity through gut microbiota remains controversial in existing RCTs. Furthermore, to our knowledge, there is no systematic review to evaluate the effect of probiotics on brain activity through gut microbiota. Therefore, we aim to summarize literatures evaluating the potential association between probiotics, gut microbiota and brain activity to elucidate whether probiotics influence gut microbiota and affect brain activity through gut microbiota.

**Methods and analysis** CNKI, Wanfang Data, VIP Databases, SinoMed, PubMed, Web of Science, MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Cochrane Library CENTRAL were searched until July 2019. The Grey Literature in Europe (OpenSIGLE) database and Google search engine were also used. The reference lists of each included study were reviewed to determine whether there were any further relevant studies. RCTs using probiotics alone or with prebiotics (synbiotics) compared with a placebo/control will be included. We will use risk of bias assessment and the GRADE System to assess the quality of evidence. The results of the systematic review will be synthesized narratively in the domains of the three primary outcome measures: the changes in brain function and their association with the changes in clinical symptoms after probiotics' administration; the changes in composition or diversity of gut microbiota and their association with the changes in

1  
2  
3 clinical symptoms after probiotics' administration; the relationship between the  
4 functional alteration area of the brain and the changes in composition or diversity of  
5 gut microbiota after probiotics' administration.  
6  
7

8  
9 **Ethics and dissemination** The results will be disseminated through a peer-reviewed  
10 publication. As no private and confidential patient data will be included in the  
11 reporting, there are no ethical considerations associated with this protocol.  
12  
13

14  
15 **PROSPERO registration number** CRD42019145114  
16

## 17 **Article Summary**

### 18 **Strengths and limitations of this study**

- 19 1. This is the first systematic review assessing the potential association between  
20 probiotics, gut microbiota and brain activity.
- 21 2. The study design adheres to all relevant guidelines for systematic reviews and  
22 meta-analysis.
- 23 3. The quality of evidence will be assessed by the GRADE system.
- 24 4. This systematic review will have inherent limitations related to the included studies  
25 such as risk of bias, methodological inconsistencies and incomplete outcome data.
- 26 5. We will only retrieve data from Chinese and English databases, which may limit  
27 available data or result in language bias.

## 28 **Background**

29 Probiotics are defined as "live microorganisms" that provide health benefits to  
30 the host when consumed in adequate amounts.<sup>1</sup> The use of probiotics has emerged as  
31 a principal approach to maintain the balance of the human gut microbiota.<sup>2</sup>

32 Probiotics have a strong ability to modulate the gut microbiota composition in healthy  
33 subjects,<sup>3-4</sup> leading to a significant reduction in several bacterial genera directly  
34 involved in the onset of gastrointestinal diseases.<sup>3</sup> Furthermore, probiotics regulate the  
35 gut microbiota of patients with gastrointestinal diseases and improve clinical  
36 symptoms.<sup>5-6</sup> These findings show that probiotics can be used to treat gastrointestinal  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 diseases by maintaining or changing the gut microbiota.  
4

5  
6 The gut microbiota includes bacteria, fungi, archaea, protozoa and viruses that  
7 interact with the host and each other to affect the host's physiology and health.<sup>7</sup> The  
8 microbiota has recently emerged as a key player in the gut-brain axis. This interaction  
9 between the brain and the microbiota has led to the recognition of a new term called  
10 'microbiota-gut-brain axis'.<sup>8</sup> This interaction is bidirectional, meaning that  
11 disturbance in the complex community of microbiota (dysbiosis) can affect the brain  
12 and vice versa.<sup>9</sup> In clinical trials, neurological disorders were linked to gastrointestinal  
13 dysfunction and changes in gut microbiota.<sup>10</sup> *Candida albicans* exposure has been  
14 found to be associated with gastrointestinal dysfunction and impaired cognitive  
15 ability.<sup>11</sup> A meta-analysis that was performed on 13 studies up until 2016 has shown  
16 that there were significant differences in the levels of *Lactobacillus*, *Bifidobacterium*  
17 and *Faecalibacterium prausnitzii* in irritable bowel syndrome (IBS) patients  
18 compared with healthy controls.<sup>12</sup> Alteration in gut microbiota may contribute to IBS  
19 pathogenesis by altering the gut-brain axis.<sup>13</sup>  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 The underlying signaling mechanisms of these communicating networks between  
32 the gut flora and the gut-brain axis have been of special interest to researchers who  
33 are seeking potential therapeutic interventions.<sup>9</sup> The ingestion of probiotics by healthy  
34 humans showed diminished psychological symptoms, including anxiety symptoms,<sup>14</sup>  
35 while probiotic intervention significantly ameliorated the severity of depression in  
36 major depressive disorder patients,<sup>15</sup> and IBS patients.<sup>16</sup> The above results show that  
37 probiotics affect central nervous system diseases and this effect may be exerted  
38 through the microbiota-gut-brain axis. A study has systematically reviewed the effects  
39 of probiotics on central nervous system function in animals and humans suggesting  
40 that more research using both behavioral and neuroimaging measures on healthy  
41 volunteers and patients is needed in the future.<sup>17</sup> Furthermore, most of the  
42 psychological assessments in clinical trials were based solely on self-reported  
43 measures, hence firm conclusions regarding the effects of probiotics on the central  
44 nervous system cannot be drawn from these findings.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 Given the difficulty of studying the brain at the cellular level in humans,  
57 neuroimaging has emerged as a tool for increasing our understanding of the  
58 microbiota-gut-brain axis. Advances in computational biology are beginning to  
59  
60

1  
2  
3 explain how these multifaceted and complex systems interact with each other.<sup>18-19</sup>  
4  
5 Functional magnetic resonance imaging (fMRI) is able to measure moment-to-  
6  
7 moment alterations in the blood oxygen content (the blood oxygen level dependent or  
8  
9 BOLD signal).<sup>20</sup> Furthermore, it enables us to identify real-time changes in  
10  
11 neurological activity and correlate these with changes in behavior or perception.<sup>17,21-22</sup>  
12  
13 fMRI has been used successfully to identify differences in brain function in  
14  
15 gastrointestinal disease states, such as IBS and inflammatory bowel disease, as well as  
16  
17 in healthy people before and after chronic ingestion of probiotics.<sup>20,23-24</sup> Using fMRI,  
18  
19 enables us to examine whether probiotics influence the gut microbiota and affect brain  
20  
21 activity through the gut microbiota. It helps us better understand the microbiota-gut-  
22  
23 brain axis, to develop a potential therapeutic method for central nervous system  
24  
25 diseases in the future.

26  
27 Recently, there were RCTs that focused on brain activity changes detected by  
28  
29 fMRI and gut microbiota composition changes after using probiotic supplements.  
30  
31 However, the effect of probiotics on brain activity through gut microbiota remains  
32  
33 controversial in existing RCTs.<sup>16,23,25</sup> Furthermore, to our knowledge, there is no  
34  
35 systematic review to evaluate the effect of probiotics on brain activity through gut  
36  
37 microbiota. Therefore, we plan to systematically analyze all published RCTs in the  
38  
39 medical literature to assess the effects of probiotics on the gut microbiota and brain  
40  
41 activities. This will improve our understanding of the microbiota-gut-brain axis.  
42  
43 Moreover, a deeper understanding of the underlying mechanisms will help refine the  
44  
45 clinical use of probiotic supplements in the future.

## 43 Objectives

46  
47 The objective of this systematic review is to summarize the literature evaluating  
48  
49 the potential association between probiotics, gut microbiota and brain activity. fMRI  
50  
51 of the participants after taking probiotics of any type, dosage, time point and duration  
52  
53 will be evaluated. To this end, we aim to:

- 54 (1) Evaluate the relationship between the changes in clinical symptoms and the  
55  
56 functional alteration area of the brain after probiotics' administration.
- 57  
58 (2) Evaluate the relationship between the changes in clinical symptoms and the  
59  
60 changes in composition or diversity of gut microbiota after probiotics' administration.

(3) Evaluate the relationship between the functional alteration area of the brain and the changes in composition or diversity of gut microbiota after probiotics' administration.

We aim to determine whether probiotics influence gut microbiota and affect brain activity through the gut microbiota.

## Methods

### Retrieval strategy

The following databases were searched until July 2019 for relevant RCTs: China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Databases, SinoMed, PubMed, Web of Science, MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Cochrane Library CENTRAL. The Grey Literature in Europe (OpenSIGLE) database and Google search engine were also searched. Furthermore, reference lists of each included study were reviewed to determine whether there were any further relevant studies. The search terms and search strategy are shown in Table 1:

Table 1. Search terms and search strategy

1.probiotic	16.fermented milk
2.culturelle	17.fMRI
3.Bifidobacteria	18.MRI
4.Lactobailli	19.MR
5.Acidophilus	20.functional magnetic resonance imaging
6.yogurt	21.magnetic resonance imaging
7.gut microbiota	22.neuroimaging
8.yeast	23.brain activity
9.Saccharomyces	24.MR tomography
10.prebiotic	25.NMR Imaging

11.Synbiotics	26.脑功能成像
12.Bacillus	27.核磁共振成像
13.enterococcus	28.功能性磁共振
14.streptococcus	29.益生菌
15.sour milk	30.益生元
	31.肠道菌群
32.“probiotic-related” terms	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16
33.“fMRI-related” terms	17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 24 OR 25
FINAL SEARCH TERMS	“32” AND “33”
FINAL SEARCH TERMS FOR CHINESE DATABASES	“29 OR 30 OR 31” AND “26 OR 27 OR 28”

---

### **Inclusion criteria**

- (1) Type of study: clinical randomized controlled trials.
- (2) Participants: healthy individuals or patients.
- (3) Interventions: probiotics alone or together with prebiotics (synbiotics) compared with a placebo/control.
- (4) Outcomes: primary outcomes: brain imaging data obtained from fMRI and their association with clinical symptoms after using probiotics; changes in composition and diversity of the gut microbiota and their association with clinical symptoms after using probiotics; relationship between the functional alteration area of the brain and the changes in composition or diversity of the gut microbiota after probiotics' administration. Secondary outcomes: adverse events and participants' compliance during the trial.

### **Exclusion criteria**

- 1
- 2
- 3 (1) Non-clinical randomized controlled trials.
- 4
- 5
- 6 (2) Editorials, literature reviews, and meta-analyses.
- 7
- 8
- 9 (3) Duplicate publications.
- 10
- 11 (4) Studies without full report of study results or primary data.
- 12

### 13 **Outcome measures**

14  
15  
16 The primary outcome measures for this review will be the assessment of brain  
17 activity changes, which were measured by fMRI, as they relate to gut microbiota  
18 regulated by probiotics.  
19

20  
21  
22 Three different primary outcome measures will be obtained from the following  
23 primary research:  
24

- 25
- 26 (1) The functional alteration area of the brain and its association with the changes in  
27 clinical symptoms after probiotics' administration.
- 28
- 29
- 30 (2) The changes in composition or diversity of the gut microbiota and their association  
31 with the changes in clinical symptoms after probiotics' administration.  
32
- 33
- 34
- 35 (3) The relationship between the functional alteration area of the brain and the changes  
36 in composition or diversity of the gut microbiota after probiotics' administration.  
37
- 38

39 Secondary outcome measures: the relevant adverse events and participants'  
40 compliance.  
41

### 42 **Study selection**

43  
44  
45 All the studies retrieved through the search strategy will first be screened based  
46 on title and abstract using ENDNOTE, which can remove duplicates. Two reviewers  
47 will independently screen all titles and abstracts according to the inclusion criteria.  
48 Any disagreements will be resolved by discussion or a third reviewer. Full text of  
49 potentially eligible studies based on title and abstract will be screened for eligibility  
50 by two reviewers independently; disagreements will be resolved by discussion or a  
51 third reviewer if necessary. Reasons for study exclusions will be recorded.  
52  
53  
54  
55  
56  
57

### 58 **Data extraction**

1  
2  
3 Data will be extracted from each eligible study including the following  
4 information: authors; year of publication; journal; sample size; demographic  
5 characteristics of sample (age, ethnicity, sex); any information (e.g. type, duration,  
6 dose, time point) we can get on the intervention group and control/placebo group; data  
7 analysis strategy used; fMRI data analysis strategy used; outcomes (the functional  
8 alteration area of the brain and its association with the changes in clinical symptoms  
9 after probiotics' administration; gut microbiota composition or diversity changes and  
10 their association with the changes in clinical symptoms after probiotics'  
11 administration; relationship between the functional alteration area of the brain and the  
12 changes in composition or diversity of gut microbiota after probiotics' administration;  
13 adverse events and participants' compliance, and conclusions.  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Quality assessment**

24  
25 Risk of bias assessment: the included studies will be assessed by two  
26 independent investigators using the Cochrane Risk of Bias Assessment Tool.<sup>26</sup> The  
27 assessment will include contents of random sequence generation, allocation  
28 concealment, blinding (of participants, personnel and outcome assessors), incomplete  
29 outcome data and selective outcome reporting and other sources of bias. The  
30 investigators' judgment will be categorized as "Low risk", "High risk" or "Unclear  
31 risk" of bias. The disagreements will be resolved by discussion or a third analyzer if  
32 necessary.  
33  
34  
35  
36  
37  
38  
39  
40

41 Quality of evidence assessment: two independent reviewers will assess overall  
42 quality of evidence using the Grading of Recommendations Assessment, Development  
43 and Evaluation (GRADE) system, examining the quality of the literature in five  
44 domains—risk of bias, publication bias, consistency, directness, and precision.<sup>27</sup> This  
45 system has four levels of classification ("high", "moderate", "low" and "very low") to  
46 which each study can be assigned based on different factors. Disagreements will be  
47 resolved by discussion or a third analyzer if necessary.  
48  
49  
50  
51  
52  
53

### 54 **Strategy of data synthesis**

55  
56 The results of the systematic review will be synthesized narratively in the  
57 domains of the three primary outcome measures: the functional alteration area of the  
58 brain and its association with the changes in clinical symptoms after probiotics'  
59  
60

1  
2  
3 administration; the changes in composition or diversity of the gut microbiota and their  
4 association with the changes in clinical symptoms after probiotics' administration;  
5  
6  
7 relationship between the functional alteration area of the brain and the changes in  
8 composition or diversity of the gut microbiota after probiotics' administration, and  
9 one secondary outcome measure: the relevant adverse events and participants'  
10 compliance. We will extract the functional alteration area of the brain to evaluate  
11 whether probiotics are effective in changing particular brain regions, where the altered  
12 regions in the brain are, and whether the altered brain regions were different between  
13 healthy individuals and patients. Additionally, we will evaluate the relationship  
14 between the changes in clinical symptoms and the functional alteration area of the  
15 brain after probiotics' administration. If possible from the number of studies  
16 available, we will use narrative review to explicate whether a "dose-dependent" or  
17 "type-dependent" relationship can be identified between probiotic supplements and  
18 brain activity changes. We will also evaluate the relationship between the changes in  
19 clinical symptoms and the changes in composition or diversity of the gut microbiota  
20 after probiotics' administration, and evaluate the relationship between the functional  
21 alteration area of the brain and the changes in composition or diversity of the gut  
22 microbiota after probiotics' administration. Finally, we will record all the adverse  
23 events and participants' compliance during the trial to assess the safety and  
24 popularization of probiotic supplements, which can be regarded as a new potential  
25 therapeutic method for central nervous system diseases in the future. To fully assess  
26 for gaps in evidence, we will do the risk of bias assessment, and the strength of  
27 evidence for this conclusion will be determined by the items evaluated in the GRADE  
28 framework described above. We will highlight areas that need further study and give  
29 suggestions for future studies.

### 47 **Registration and reporting of results**

48  
49  
50 We registered this study in PROSPERO international prospective register of  
51 systematic reviews on July 2019.<sup>28</sup> This protocol was drafted according to the  
52 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols  
53 (PRISMA).<sup>29</sup> The methods and results of the systematic review will be reported in  
54 accordance with the PRISMA guidelines.<sup>30</sup>

### 59 **Patient and public involvement**

No patients or public will be involved in this systematic review protocol.

## Discussion

With the increasing annual growth in industrial production of food containing probiotics worldwide, the interest in elucidating how changes in the gut microbiota and changes in brain activity as a result of probiotics ingestion can serve as a new way for treating subjects with central nervous system diseases is increasing. In our systematic review, we will synthesize the evidence evaluating the association between probiotic supplements and brain activity changes and gut microbiota changes in humans to decipher whether probiotics influence brain activity and whether the effect of probiotics on brain activity is associated with changes in gut microbiota. This review provides a new way of thinking about the treatment of central nervous system diseases and health maintenance. To our knowledge, this will be the first systematic review focused on this topic.

Additionally, from the adverse events and participants' compliance with probiotic supplements, we can accumulate evidence for the popularization of probiotic therapy, which may be used to treat central system diseases in the future. This can help better understand probiotics' clinical application, effectiveness, and safety.

Furthermore, we will determine gaps or uncertainties in the existing literature, which requires further study. However, given the potential implications of such an association, this review will provide a solid foundation for the design and implementation of future studies that can better clarify the relationship between probiotics and gut microbiota and brain activities in humans.

## Acknowledgements

We thank Michal Bell, from Liwen Bianji, Edanz Editing China ( [www.liwenbianji.cn/](http://www.liwenbianji.cn/) ac) for editing the English text of a draft of this manuscript.

## Author's Contributions

LL developed the search strategy, TT and XL will search the databases and screen the eligibility of the retrieved studies. FL and XN will extract information from the

1  
2  
3 eligible studies and prepare the information for data analysis. JC,MS and SZ will  
4 perform the data analysis. LL and LZ wrote the first draft of the protocol. In practice,  
5 LZ will monitor each procedure of the review and is responsible for quality control.  
6  
7 All authors read the article and approved it for publication. All authors read and  
8 approved the final manuscript and order of authorship.  
9  
10  
11

## 12 **Funding**

13  
14  
15 The review is supported by the National Key Research and Development  
16 Project(Grant No.2019YFC1709701),the National Natural Science Foundation of  
17 China (Grant No.81722050, 81973962) and the Interdisciplinary Program of Chengdu  
18 University of Traditional Chinese Medicine (Grant No.CZYJC1901). Funders and  
19 sponsors have no role in the design of this protocol.  
20  
21  
22  
23

## 24 **Competing interests**

25  
26 None declared  
27  
28  
29

## 30 **References**

- 31  
32  
33 1. Hill, C., F. Guarner, G. Reid, et al. "Expert consensus document.The International  
34 Scientific Association for Probiotics and Prebiotics consensus statement on the scope  
35 and appropriate use of the term probiotic." *Nat Rev Gastroenterol Hepatol* 11(8):506-  
36 514.  
37  
38  
39  
40 2. Hardy H, Harris J, Lyon E, et al. Probiotics, prebiotics and immunomodulation of  
41 gut mucosal defences: Homeostasis and immunopathology. *Nutrients* 2013;5:1869-  
42 912.  
43  
44  
45  
46 3. Toscano M,De Grandi, R.Miniello, V. L, et al. Ability of *Lactobacillus kefir*  
47 LKF01 (DSM32079) to colonize the intestinal environment and modify the gut  
48 microbiota composition of healthy individuals. *Dig Liver Dis.*2017;49(3):261-267.  
49  
50  
51  
52 4. Toscano M, De Grandi R, Stronati L, et al.Effect of *Lactobacillus rhamnosus*  
53 HN001 and *Bifidobacterium longum* BB536 on the healthy gut microbiota  
54 composition at phyla and species level:A preliminary study. *World J Gastroenterol*  
55 2017;23(15):2696-2704.  
56  
57  
58  
59  
60



- 1  
2  
3 properties of a probiotic formulation (*Lactobacillus helveticus* R0052 and  
4 *Bifidobacterium longum* R0175) in rats and human subjects. *Br J Nutr*. 2011  
5  
6  
7 Mar;105(5):755-64.  
8  
9
- 10 15. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al. Clinical and metabolic  
11  
12 response to probiotic administration in patients with major depressive disorder:  
13  
14 A randomized, double-blind, placebo-controlled trial. *Nutrition*. 2016 Mar;32(3):315-  
15  
16 20.  
17  
18
- 19 16. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic *Bifidobacterium longum*  
20  
21 NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in  
22  
23 Patients With Irritable Bowel Syndrome. *Gastroenterology*. 2017 Aug;153(2):448-  
24  
25 459.e8.  
26  
27
- 28 17. Wang H, Lee IS, Braun C, et al. Effect of Probiotics on Central Nervous  
29  
30 System Functions in Animals and Humans: A Systematic Review. *J*  
31  
32 *Neurogastroenterol Motil*. 2016 Oct 30;22(4):589-605.  
33  
34
- 35 18. Malan-Muller S, Valles-Colomer M, Raes J, et al. The Gut Microbiome and  
36  
37 Mental Health: Implications for Anxiety- and Trauma-Related Disorders. *OMICS*.  
38  
39 2018 Feb;22(2):90-107.  
40  
41
- 42 19. Cong X, Henderson WA, Graf J, et al. Early Life Experience and Gut  
43  
44 Microbiome: The Brain-Gut-Microbiota Signaling System. *Adv Neonatal Care*. 2015  
45  
46 Oct;15(5):314-23; quiz E1-2.  
47  
48
- 49 20. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain  
50  
51 regions activated during rectal distension in irritable bowel syndrome.  
52  
53 *Gastroenterology*. 2011 Jan;140(1):91-100.  
54  
55
- 56 21. Lener MS, Niciu MJ, Ballard ED, et al. Glutamate and Gamma-Aminobutyric  
57  
58 Acid Systems in the Pathophysiology of Major Depression and Antidepressant  
59  
60 Response to Ketamine. *Biol Psychiatry*. 2017 May 15;81(10):886-897.

- 1  
2  
3 22. Al Omran Y, Aziz Q. Functional brain imaging in gastroenterology: to new  
4  
5 beginnings. *Nat Rev Gastroenterol Hepatol*. 2014 Sep;11(9):565-76.  
6  
7  
8 23. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product  
9  
10 with probiotic modulates brain activity. *Gastroenterology*. 2013 Jun;144(7):1394-401,  
11  
12 1401.e1-4.  
13  
14 24. Agostini A, Filippini N, Cevolani D, et al. Brain functional changes in patients  
15  
16 with ulcerative colitis: a functional magnetic resonance imaging study on emotional  
17  
18 processing. *Inflamm Bowel Dis*. 2011 Aug;17(8):1769-77.  
19  
20 25. Bagga D, Reichert JL, Koschutnig K, et al. Probiotics drive gut microbiome  
21  
22 triggering emotional brain signatures. *Gut Microbes*. 2018 Nov 2;9(6):486-496.  
23  
24 26. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool  
25  
26 for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. Published 2011  
27  
28 Oct 18.  
29  
30 27. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series  
31  
32 of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol*. 2011;64(4):380–  
33  
34 382.  
35  
36 28. Lu Liu, Xi Xiu NI, TIAN TIAN, et al. Effect of regulating gut microbiota using  
37  
38 probiotics on brain activity: protocol of a systematic review. PROSPERO 2019  
39  
40 CRD42019145114. Available: [http://www.crd.york.ac.uk/PROSPERO/display\\_record.  
41  
42 asp?ID=CRD42019145114](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42019145114)  
43  
44  
45 29. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic  
46  
47 review and meta- analysis protocols (PRISMA- P) 2015: elaboration and explanation.  
48  
49 *BMJ* 2015;350:g7647.  
50  
51 30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic  
52  
53 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4:1.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1 Search terms and strategy

1.probiotic	16.fermented milk
2.culturelle	17.fMRI
3.Bifidobacteria	18.MRI
4.Lactobacilli	19.MR
5.Acidophilus	20.functional magnetic resonance imaging
6.yogurt	21.magnetic resonance imaging
7.gut microbiota	22.neuroimaging
8.yeast	23.brain activity
9.Saccharomyces	24.MR tomography
10.prebiotic	25.NMR Imaging
11.Synbiotics	26.脑功能成像
12.Bacillus	27.核磁共振成像
13.enterococcus	28.功能性磁共振
14.streptococcus	29.益生菌
15.sour milk	30.益生元
	31.肠道菌群
32."probiotic-related" terms	1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16
33."fMRI-related" terms	17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 24 OR 25
FINAL SEARCH TERMS	"32" AND "33"
FINAL SEARCH TERMS FOR CHINESE DATABASES	"29 OR 30 OR 31" AND "26 OR 27 OR 28"

# BMJ Open

## Effect of regulating gut microbiota using probiotics on functional changes in the brain: protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037582.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Apr-2020
Complete List of Authors:	Liu, Lu; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina Ni, Xixiu; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina Tian, Tian; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina Li, Xiao; Chengdu University of TCM, Acupuncture and Tuina School Li, Fengmei; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina Sun, Mingsheng; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina Chen, Jiao; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina Zhou, SiYuan; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina, Zhao, Ling; Chengdu University of Traditional Chinese Medicine, College of Acupuncture and Moxibustion and Tuina
<b>Primary Subject Heading</b>:	Complementary medicine
Secondary Subject Heading:	Public health, Neurology, Mental health, Diagnostics
Keywords:	Microbiology < BASIC SCIENCES, Neurobiology < BASIC SCIENCES, Neuropathology < NEUROLOGY, Microbiology < PATHOLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, Head & neck imaging < RADIOLOGY & IMAGING

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Effect of regulating gut microbiota using probiotics on functional changes in the brain: protocol for a systematic review

Lu Liu,Xixiu Ni,Tian Tian,Xiao Li,Fengmei Li,Mingsheng Sun,Jiao Chen,Siyuan Zhou,Ling Zhao

Acupuncture and Tuina School, Chengdu University of TCM, Chengdu, 610075, Sichuan, China

## Authors:

Lu Liu, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075,China;liulu@stu.cdutcm.edu.cn

Xixiu Ni, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075,China;nixixiu@stu.cdutcm.edu.cn

Tian Tian, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; tiantian@stu.cdutcm.edu.cn

Xiao Li, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China;1039061367@qq.com

Fengmei Li, MD: Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China;lifengmei@stu.cdutcm.edu.cn

Mingsheng Sun, PhD: Acupuncture and Tuina School, Chengdu University of

1  
2  
3 Traditional Chinese Medicine, Chengdu, Sichuan 610075, China; sunmingsheng@stu.  
4  
5  
6 cdutcm.edu.cn  
7

8 Jiao Chen, PhD: Acupuncture and Tuina School, Chengdu University of Traditional  
9 Chinese Medicine, Chengdu, Sichuan 610075, China; chenjiao@cdutcm.edu.cn  
10  
11  
12  
13  
14  
15  
16

### 17 Corresponding authors

18  
19  
20 Ling Zhao, PhD: Acupuncture and Tuina School, Chengdu University of Traditional  
21 Chinese Medicine, No.37 Shier Qiao Road, Chengdu, Sichuan 610075, China;  
22  
23 Tel: +8602887687008; zhaoling@cdutcm.edu.cn;  
24  
25

26 Siyuan Zhou, PhD: Acupuncture and Tuina School, Chengdu University of  
27 Traditional Chinese Medicine, No.37 Shier Qiao Road, Chengdu, Sichuan 610075,  
28  
29 China; Tel: +8602887687008; zsy@cdutcm.edu.cn  
30  
31  
32  
33  
34  
35  
36

37 Word Count:

38  
39  
40 2,540 words  
41  
42  
43  
44  
45  
46  
47

48 Key Words:

49  
50 probiotics, gut microbiota, functional changes in the brain, fMRI, increased/decreased  
51 activity in brain regions, altered functional connectivity  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction** There is a growing number of randomized controlled trials (RCTs) that focus on functional changes in the brain detected by functional magnetic resonance imaging (fMRI) and gut microbiota composition changes after using probiotics.

However, the effect of probiotics on functional changes in the brain through gut microbiota remains controversial in existing RCTs. Furthermore, to our knowledge, there is no systematic review to evaluate the effect of probiotics on functional changes in the brain through gut microbiota. Therefore, we aim to summarize literatures evaluating the potential association between probiotics, gut microbiota and functional changes in the brain to elucidate whether probiotics influence gut microbiota and

1  
2  
3 affect functional changes in the brain through gut microbiota.  
4

5  
6 **Methods and analysis** CNKI,Wanfang Data,VIP Databases,SinoMed,PubMed,Web  
7 of Science,MEDLINE,EMBASE,Scopus,the Cochrane Central Register of Controlled  
8 Trials, ClinicalTrials.gov and Cochrane Library CENTRAL will be searched until  
9 July 2019. The Grey Literature in Europe (OpenSIGLE) database and Google search  
10 engine will also be used.The reference lists of each included study will be reviewed to  
11 determine whether there are any further relevant studies.RCTs using probiotics  
12 compared with a placebo/control will be included.We will use risk of bias assessment  
13 and the GRADE System to assess the quality of evidence.The results of the systematic  
14 review will be synthesized narratively in the domains of the three primary outcome  
15 measures:1) increased/decreased activity in brain regions or altered functional  
16 connectivity(FC) of brain detected by fMRI and their association with changes in  
17 behaviour,gastrointestinal/emotional symptoms after using probiotics;2) changes in  
18 composition and diversity of the gut microbiota and their association with changes in  
19 behaviour,gastrointestinal/emotional symptoms after using probiotics;3) increased/  
20 decreased activity in brain regions or altered FC of brain detected by fMRI and the  
21 changes in composition or diversity of the gut microbiota after probiotics'  
22 administration.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Ethics and dissemination** The results will be disseminated through a peer-reviewed  
38 publication. As no private and confidential patient data will be included in the  
39 reporting, there are no ethical considerations associated with this protocol.  
40  
41  
42

43 **PROSPERO registration number** CRD42019145114  
44

## 45 **Article Summary**

### 46 **Strengths and limitations of this study**

- 47  
48  
49  
50  
51  
52 1. This is the first systematic review assessing the potential association between  
53 probiotics, gut microbiota and functional changes in the brain.  
54  
55  
56 2. The study design adheres to all relevant guidelines for systematic reviews and  
57 meta-analyses.  
58  
59  
60

- 1
- 2
- 3 3. The quality of evidence will be assessed by the GRADE system.
- 4
- 5
- 6 4. This systematic review will have inherent limitations related to the included studies
- 7 such as risk of bias, methodological inconsistencies and incomplete outcome data.
- 8
- 9
- 10 5. We will only retrieve data from Chinese and English databases, which may limit
- 11 available data or result in language bias.
- 12
- 13

## 14 **Background**

15  
16  
17 Probiotics are defined as “live microorganisms” that provide health benefits to  
18 the host when consumed in adequate amounts.<sup>1</sup> The use of probiotics has emerged as a  
19 principal approach to maintain the balance of the human gut microbiota.<sup>2</sup> Probiotics  
20 have a strong ability to modulate the gut microbiota composition in healthy subjects,<sup>3-</sup>  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
4 leading to a significant reduction in several bacterial genera directly involved in the  
onset of gastrointestinal diseases.<sup>3</sup> Furthermore, probiotics regulate the gut microbiota  
of patients with gastrointestinal diseases and improve clinical symptoms.<sup>5-6</sup> These  
findings show that probiotics can be used to treat gastrointestinal diseases by  
maintaining or changing the gut microbiota.

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
The gut microbiota includes bacteria, fungi, archaea, protozoa and viruses that  
interact with the host and each other to affect the host’s physiology and health.<sup>7</sup> The  
microbiota has recently emerged as a key player in the gut-brain axis. This interaction  
between the brain and the microbiota in both animals and humans has led to the  
recognition of a new term called ‘microbiota-gut-brain axis’.<sup>8</sup> This interaction is  
bidirectional, meaning that disturbance in the complex community of microbiota  
(dysbiosis) can affect the brain and vice versa.<sup>9</sup> A meta-analysis that was performed  
on 13 studies up until 2016 has shown that there were significant differences in the  
levels of *Lactobacillus*, *Bifidobacterium* and *Faecalibacterium prausnitzii* in irritable  
bowel syndrome (IBS) patients compared with healthy controls.<sup>10</sup> Alteration in gut  
microbiota may contribute to pathogenesis of IBS patients by altering the gut-brain  
axis.<sup>11</sup> Patients with neurological disorders were linked to gastrointestinal dysfunction  
and changes in gut microbiota.<sup>12</sup> And in another clinical trial, *Candida albicans*  
exposure has been found to be associated with gastrointestinal dysfunction and  
impaired cognitive ability.<sup>13</sup> The underlying signaling mechanisms of these  
communicating networks between the gut flora and the gut-brain axis have been of

1  
2  
3 special interest to researchers who are seeking potential therapeutic interventions.<sup>9</sup>  
4

5  
6 The ingestion of probiotics by healthy humans showed diminished psychological  
7 symptoms, including anxiety symptoms,<sup>14</sup> while probiotic intervention significantly  
8 ameliorated the severity of depression in major depressive disorder patients,<sup>15</sup> and IBS  
9 patients.<sup>16</sup> The above results show that gut microbiota is related to various diseases,  
10 and that modulating gut microbiota through probiotics may offer a potential treatment  
11 option. However, most of the psychological assessments in clinical trials<sup>14,15,17</sup> were  
12 based solely on self-reported measures, hence firm conclusions regarding the effects  
13 of probiotics cannot be drawn from these findings.  
14  
15  
16  
17  
18  
19

20  
21 Given the difficulty of studying the brain at the cellular level in humans,  
22 neuroimaging has emerged as a tool for increasing our understanding of the brain.  
23 Advances in computational biology are beginning to explain how these multifaceted  
24 and complex systems interact with each other.<sup>18-19</sup> Neuroimaging tools as outcome  
25 measures are more objective than self-reported measures, which is an advantage over  
26 self-reported measures. fMRI is able to measure moment-to-moment alterations in the  
27 blood oxygen content (the blood oxygen level dependent or BOLD signal).<sup>20</sup>  
28 Furthermore, it enables us to identify real-time changes in neurological activity and  
29 correlate these with changes in behavior or perception.<sup>21-23</sup> fMRI has been used  
30 successfully to identify differences in brain function in gastrointestinal disease states,  
31 such as IBS and inflammatory bowel disease, as well as in healthy people before and  
32 after chronic ingestion of probiotics.<sup>20,24-25</sup> fMRI is effective predominantly because of  
33 its non-invasiveness, and it can accurately and intuitively observe the location and  
34 range of brain functional activity from the whole level under physiological  
35 condition.<sup>26</sup> Using task based fMRI or resting-state fMRI (rsfMRI), enables us to  
36 examine whether probiotics influence the gut microbiota and affect activity in brain  
37 regions or FC of brain through the gut microbiota. It helps us better understand the  
38 microbiota-gut-brain axis, to potentially help develop therapeutic methods for central  
39 nervous system diseases in the future.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 Recently, there were RCTs that focused on increased/decreased activity in brain  
55 regions<sup>24,27-28</sup> or altered FC of brain<sup>24,29</sup> detected by task based fMRI or rs-fMRI after  
56 using probiotics in healthy subjects. However, some studies have found changes in gut  
57 microbiota,<sup>27-28</sup> behaviour, gastrointestinal/emotional symptoms,<sup>27</sup> while others have  
58  
59  
60

1  
2  
3 not.<sup>24</sup> Furthermore, to our knowledge, there is no systematic review to evaluate the  
4 effect of probiotics on functional changes in the brain through gut microbiota.  
5 Therefore, we plan to systematically analyze all published RCTs in the medical  
6 literature to assess the effects of probiotics on the gut microbiota and functional  
7 changes in the brain. This will improve our understanding of the microbiota-gut-brain  
8 axis. Moreover, a deeper understanding of the underlying mechanisms will help refine  
9 the clinical use of probiotic supplements in the future.

## 16 Objectives

17  
18  
19 The objective of this systematic review is to summarize the literature evaluating  
20 the potential association between probiotics, gut microbiota and increased/decreased  
21 activity in brain regions or altered FC of brain in the healthy subjects after taking  
22 probiotics of any type, dosage, time point and duration will be evaluated. To this end,  
23 we aim to:  
24  
25  
26

- 27  
28 (1) Evaluate the relationship between the changes in behaviour, gastrointestinal/  
29 emotional symptoms and increased/decreased activity in brain regions or altered FC  
30 of brain after probiotics' administration.  
31  
32 (2) Evaluate the relationship between the behaviour, gastrointestinal/emotional  
33 symptoms and the changes in composition or diversity of gut microbiota after  
34 probiotics' administration.  
35  
36 (3) Evaluate the relationship between increased/decreased activity in brain regions or  
37 altered FC of brain and the changes in composition or diversity of gut microbiota after  
38 probiotics' administration.  
39  
40  
41  
42  
43  
44  
45  
46

47  
48 We aim to determine whether probiotics influence gut microbiota and affect  
49 functional changes in the brain through the gut microbiota.  
50  
51

## 52 Methods

### 53 Retrieval strategy

54  
55 The following databases will be searched until July 2019 for relevant RCTs: China  
56 National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Databases, SinoMed,  
57  
58  
59  
60

PubMed, Web of Science, MEDLINE, EMBASE, Scopus, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Cochrane Library CENTRAL. The Grey Literature in Europe (OpenSIGLE) database and Google search engine will also be searched. Furthermore, reference lists of each included study will be reviewed to determine whether there are any further relevant studies. The search terms will include probiotics (eg, “probiotics” or “culturelle” or “bifidobacteria” or “lactobacilli” or “escherichia coli” or “yogurt” or “yeast” or “saccharomyces” or “bacillus” or “enterococcus” or “streptococcus” or “fermented milk” or “sour milk” or “gastrointestinal microbiome” or “gut microbiota” or “gut microbiome” or “gut microflora” or “intestinal microflora” or “intestinal bacteria” or “intestinal microbiome” or “microbiome” or “microbiota” or “bacteria” or “flora”), fMRI (eg, “magnetic resonance imaging” or “fMRI” or “functional magnetic resonance imaging” or “neuroimaging” or “MRI” or “brain activity” or “MR tomography” or “NMR Imaging” or “MR” or “independent component analysis” or “functional network connectivity” or “amplitude of low frequency fluctuations” or “regional homogeneity” or “functional connectivity” or “central” or “brain” or “neuro” or “ALFF” or “FALFF” or “REHO” or “ROI” or “FC” or “ICA”). The following terms will be used in the Chinese database searches: “Yi sheng jun”, “Chang dao jun qun”, “Jun qun”, “Nao gong neng cheng xiang”, “Gong neng xing ci gong zhen”, “He ci gong zhen cheng xiang” and “He ci”. The search strategy for the PubMed database is shown in Table 1 (in the supplementary file), this strategy will be modified appropriately for other databases.

### **Inclusion criteria**

- (1) Type of study: randomized clinical controlled trials.
- (2) Participants: healthy individuals
- (3) Interventions: probiotics compared with a placebo/control.
- (4) Outcomes measures: the primary outcome measures for this review will be the assessment of functional changes in the brain, which were measured by fMRI, as they relate to gut microbiota regulated by probiotics. Three different primary outcome measures will be obtained from the following primary research: 1) increased/decreased activity in brain regions or altered FC of brain detected by fMRI and their association

1  
2  
3 with changes in behaviour,gastrointestinal/emotional symptoms after using probiotics;  
4

5  
6 2) changes in composition and diversity of the gut microbiota and their association  
7 with changes in behaviour,gastrointestinal/emotional symptoms after using probiotics;  
8  
9

10 3) increased/decreased activity in brain regions or altered FC of brain detected by  
11 fMRI and the changes in composition or diversity of the gut microbiota after  
12 probiotics' administration.Secondary outcomes: adverse events and participants'  
13 compliance during the trial.  
14  
15  
16

### 17 **Exclusion criteria**

18  
19  
20 (1) Non-randomized clinical controlled trials.  
21

22  
23 (2) Editorials, literature reviews, and meta-analyses.  
24

25  
26 (3) Duplicate publications.  
27

28 (4) Studies without full report of study results or primary data.  
29

### 30 **Study selection**

31  
32 All the studies retrieved through the search strategy will first be screened based  
33 on title and abstract using ENDNOTE, which can remove duplicates. Two reviewers  
34 will independently screen all titles and abstracts according to the inclusion criteria.  
35 Any disagreements will be resolved by discussion or a third reviewer. Full text of  
36 potentially eligible studies based on title and abstract will be screened for eligibility  
37 by two reviewers independently; disagreements will be resolved by discussion or a  
38 third reviewer if necessary. Reasons for study exclusions will be recorded.  
39  
40  
41  
42  
43  
44  
45

### 46 **Data extraction**

47  
48 Data will be extracted from each eligible study including the following information:  
49 authors; year of publication; journal; sample size; demographic characteristics of  
50 sample (age, ethnicity, sex); any information (e.g. type, duration, dose, time point) we  
51 can get on the intervention group and control/placebo group; data analysis strategy  
52 used;fMRI data analysis strategy used; outcomes,and conclusions.  
53  
54  
55  
56  
57

### 58 **Quality assessment**

59  
60

1  
2  
3 Risk of bias assessment: the included studies will be assessed by two  
4 independent investigators using the Cochrane Risk of Bias Assessment Tool.<sup>30</sup> The  
5 assessment will include contents of random sequence generation, allocation  
6 concealment, blinding (of participants, personnel and outcome assessors), incomplete  
7 outcome data and selective outcome reporting and other sources of bias. The  
8 investigators' judgment will be categorized as "Low risk", "High risk" or "Unclear  
9 risk" of bias. The disagreements will be resolved by discussion or a third analyzer if  
10 necessary.  
11  
12  
13  
14  
15  
16  
17

18 Quality of evidence assessment: two independent reviewers will assess overall  
19 quality of evidence using the Grading of Recommendations Assessment, Development  
20 and Evaluation (GRADE) system, examining the quality of the literature in five  
21 domains—risk of bias, publication bias, consistency, directness, and precision.<sup>31</sup> This  
22 system has four levels of classification ("high", "moderate", "low" and "very low") to  
23 which each study can be assigned based on different factors. Disagreements will be  
24 resolved by discussion or a third analyzer if necessary.  
25  
26  
27  
28  
29  
30

### 31 **Strategy of data synthesis**

32  
33 The results of the systematic review will be synthesized narratively in the domains of  
34 the three primary outcome measures: 1) increased/decreased activity in brain regions  
35 or altered FC of brain and their association with changes in behaviour, gastrointestinal/  
36 emotional symptoms after using probiotics; 2) changes in composition and diversity of  
37 the gut microbiota and their association with changes in behaviour, gastrointestinal  
38 /emotional symptoms after using probiotics; 3) increased/decreased activity in brain  
39 regions or altered FC of brain and the changes in composition or diversity of the gut  
40 microbiota after probiotics' administration. and one secondary outcome measure: the  
41 relevant adverse events and participants' compliance. We will extract the increased/  
42 decreased activity in brain regions or altered FC of brain to evaluate whether  
43 probiotics are effective in activating/deactivating particular brain regions or are  
44 effective in altering FC of brain, where the functional changes in the brain are.  
45 Additionally, we will evaluate the relationship between the changes in behaviour,  
46 gastrointestinal/emotional symptoms and the increased/decreased activity in brain  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 regions or altered FC of brain after probiotics' administration. If possible from the  
4 number of studies available, we will use narrative review to explicate whether a  
5 "dose-dependent" or "type-dependent" relationship can be identified between  
6  
7 probiotic supplements and functional changes in the brain. We will also evaluate the  
8  
9 relationship between the changes in behaviour, gastrointestinal/emotional symptoms  
10  
11 and the changes in composition or diversity of the gut microbiota after probiotics'  
12  
13 administration, and evaluate the relationship between the increased/decreased activity  
14  
15 in brain regions or altered FC of brain and the changes in composition or diversity of  
16  
17 the gut microbiota after probiotics' administration. Finally, we will record all the  
18  
19 adverse events and participants' compliance during the trial to assess the safety and  
20  
21 popularization of probiotic supplements, which can be regarded as a new potential  
22  
23 therapeutic method for central nervous system diseases in the future. To fully assess  
24  
25 for gaps in evidence, we will do the risk of bias assessment, and the strength of  
26  
27 evidence for this conclusion will be determined by the items evaluated in the GRADE  
28  
29 framework described above. We will highlight areas that need further study and give  
30  
31 suggestions for future studies.

### 32 **Registration and reporting of results**

33  
34 We registered this study in PROSPERO international prospective register of  
35  
36 systematic reviews on July 2019.<sup>32</sup> This protocol was drafted according to the  
37  
38 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols  
39  
40 (PRISMAP).<sup>33</sup> The methods and results of the systematic review will be reported in  
41  
42 accordance with the PRISMAP guidelines.<sup>34</sup>

### 43 **Patient and public involvement**

44  
45  
46 No patients or public will be involved in this systematic review protocol.  
47  
48

### 49 **Discussion**

50  
51  
52 According to the Global Burden of Disease Study, 322 and 264 million people  
53  
54 worldwide suffered from depression and anxiety, respectively in 2015. This is an  
55  
56 increase of 18.4% and 14.9% over the 2005 figures.<sup>35</sup> There were more than 80  
57  
58 million stroke survivors in the world,<sup>36</sup> 43.8 million people with dementia,<sup>37</sup> 45.9  
59  
60 million patients with an active epilepsy,<sup>38</sup> and 6.1 million individuals with Parkinson's

1  
2  
3 disease.<sup>39</sup> Globally, in 2016, neurological disorders were the leading cause of  
4 disability (276 million disability-adjusted life-years) and the second leading cause of  
5 deaths (9 million) in the world.<sup>40</sup> With the increasing annual growth in industrial  
6 production of food containing probiotics worldwide, the interest in elucidating how  
7 changes in the gut microbiota and functional changes in brain as a result of probiotics  
8 ingestion can serve as a new way for treating subjects with central nervous system  
9 diseases is increasing. In our systematic review, we will synthesize the evidence  
10 evaluating the association between probiotic supplements and functional changes in  
11 the brain and gut microbiota changes in humans to decipher whether probiotics  
12 influence functional changes in the brain and whether the effect of probiotics on  
13 functional changes in the brain is associated with changes in gut microbiota. This  
14 review provides a new way of thinking about the treatment of central nervous system  
15 diseases and health maintenance. To our knowledge, this will be the first systematic  
16 review focused on this topic.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 Additionally, from the adverse events and participants' compliance with  
29 probiotic supplements, we can accumulate evidence for the popularization of  
30 probiotic therapy, which may be used to treat central system diseases in the future.  
31 This can help better understand probiotics' clinical application, effectiveness, and  
32 safety.

33  
34  
35  
36  
37  
38 Furthermore, we will determine gaps or uncertainties in the existing literature,  
39 which requires further study. However, given the potential implications of such an  
40 association, this review will provide a solid foundation for the design and  
41 implementation of future studies that can better clarify the relationship between  
42 probiotics and functional changes in the brain and gut microbiota and in humans.

### 43 44 45 46 47 **Acknowledgements**

48  
49 We thank Michal Bell, from Liwen Bianji, Edanz Editing China ( [www.liwenbianji.](http://www.liwenbianji.cn/)  
50 [cn/ ac](http://www.liwenbianji.cn/)) for editing the English text of a draft of this manuscript.

### 51 52 53 54 **Author's Contributions**

55  
56 LL developed the search strategy, TT and XL will search the databases and screen the  
57 eligibility of the retrieved studies. FL and XN will extract information from the  
58 eligible studies and prepare the information for data analysis. JC, MS and SZ will  
59  
60

1  
2  
3 perform the data analysis. LL and LZ wrote the first draft of the protocol. In practice,  
4 LZ will monitor each procedure of the review and is responsible for quality control.  
5 All authors read the article and approved it for publication. All authors read and  
6 approved the final manuscript and order of authorship.  
7  
8  
9

## 10 **Funding**

11  
12 The review is supported by the National Key Research and Development  
13 Project(Grant No.2019YFC1709701),the National Natural Science Foundation of  
14 China (Grant No.81722050, 81973962) and the Interdisciplinary Program of Chengdu  
15 University of Traditional Chinese Medicine (Grant No.CZYJC1901). Funders and  
16 sponsors have no role in the design of this protocol.  
17  
18  
19  
20  
21  
22

## 23 **Competing interests**

24  
25 None declared  
26  
27

## 28 **References**

- 29  
30  
31 1. Hill, C., F. Guarner, G. Reid, et al. "Expert consensus document.The International  
32 Scientific Association for Probiotics and Prebiotics consensus statement on the scope  
33 and appropriate use of the term probiotic." *Nat Rev Gastroenterol Hepatol* 11(8):506-  
34 514.  
35  
36  
37  
38 2. Hardy H, Harris J, Lyon E, et al. Probiotics, prebiotics and immunomodulation of  
39 gut mucosal defences: Homeostasis and immunopathology. *Nutrients* 2013;5:1869-  
40 912.  
41  
42  
43  
44 3. Toscano M,De Grandi, R.Miniello, V. L, et al. Ability of *Lactobacillus kefir*  
45 LKF01 (DSM32079) to colonize the intestinal environment and modify the gut  
46 microbiota composition of healthy individuals. *Dig Liver Dis.*2017;49(3):261-267.  
47  
48  
49  
50 4. Toscano M, De Grandi R, Stronati L, et al.Effect of *Lactobacillus rhamnosus*  
51 HN001 and *Bifidobacterium longum* BB536 on the healthy gut microbiota  
52 composition at phyla and species level:A preliminary study. *World J Gastroenterol*  
53 2017;23(15):2696-2704.  
54  
55  
56  
57 5. Chen L, Xu W, Lee A, et al. The impact of *Helicobacter pylori* infection,  
58  
59  
60

- 1  
2  
3 eradication therapy and probiotic supplementation on gut microenvironment  
4  
5  
6 homeostasis: An open-label, randomized clinical trial. *EBioMedicine*. 2018  
7  
8 Sep;35:87-96.  
9
- 10  
11 6. Mezzasalma V, Manfrini E, Ferri E, et al. A Randomized, Double-Blind,  
12  
13 Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation  
14  
15 in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation.  
16  
17 *Biomed Res Int*. 2016;2016:4740907.  
18
- 19  
20  
21 7. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates  
22  
23 with diet and health in the elderly. *Nature*. 2012 Aug 9;488(7410):178-84.  
24
- 25  
26 8. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. *Nat*  
27  
28 *Rev Neurosci*. 2011 Jul 13;12(8):453-66.  
29
- 30  
31 9. Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain  
32  
33 axis: What does the future hold? *World J Gastroenterol*. 2019 Feb 7;25(5):552-566.  
34
- 35  
36 10. Liu HN, Wu H, Chen YZ, et al. Altered molecular signature of intestinal  
37  
38 microbiota in irritable bowel syndrome patients compared with healthy controls: A  
39  
40 systematic review and meta-analysis. *Dig Liver Dis*. 2017 Apr;49(4):331-337.  
41
- 42  
43 11. Chong PP, Chin VK, Looi CY, et al. The Microbiome and Irritable Bowel  
44  
45 Syndrome-A Review on the Pathophysiology, Current Research and Future Therapy.  
46  
47 *Front Microbiol*. 2019 Jun 10;10:1136.  
48
- 49  
50 12. Strati F, Cavalieri D, Albanese D, et al. Altered gut microbiota in Rett syndrome.  
51  
52 *Microbiome*. 2016 Jul 30;4(1):41.  
53
- 54  
55 13. Severance EG, Gressitt KL, Stallings CR, et al. *Candida albicans* exposures, sex  
56  
57 specificity and cognitive deficits in schizophrenia and bipolar disorder. *NPJ*  
58  
59 *Schizophr*. 2016 May 4;2:16018.  
60
14. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like  
properties of a probiotic formulation (*Lactobacillus helveticus* R0052 and

- 1  
2  
3 Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr. 2011  
4  
5  
6 Mar;105(5):755-64.  
7  
8  
9 15. Akkashah G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al. Clinical and metabolic  
10  
11 response to probiotic administration in patients with major depressive disorder:  
12  
13 A randomized, double-blind, placebo-controlled trial. Nutrition. 2016 Mar;32(3):315-  
14  
15 20.  
16  
17  
18 16. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic Bifidobacterium longum  
19  
20 NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in  
21  
22 Patients With Irritable Bowel Syndrome. Gastroenterology. 2017 Aug;153(2):448-  
23  
24 459.e8.  
25  
26  
27 17. Ostadmohammadi V, Jamilian M, Bahmani F, et al. Vitamin D and probiotic  
28  
29 co-supplementation affects mental health, hormonal, inflammatory and oxidative  
30  
31 stress parameters in women with polycystic ovary syndrome. J Ovarian Res. 2019  
32  
33 Jan 21;12(1):5.  
34  
35  
36 18. Malan-Muller S, Valles-Colomer M, Raes J, et al. The Gut Microbiome and  
37  
38 Mental Health: Implications for Anxiety- and Trauma-Related Disorders. OMICS.  
39  
40 2018 Feb;22(2):90-107.  
41  
42  
43 19. Cong X, Henderson WA, Graf J, et al. Early Life Experience and Gut  
44  
45 Microbiome: The Brain-Gut-Microbiota Signaling System. Adv Neonatal Care. 2015  
46  
47 Oct;15(5):314-23; quiz E1-2.  
48  
49  
50 20. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain  
51  
52 regions activated during rectal distension in irritable bowel syndrome.  
53  
54 Gastroenterology. 2011 Jan;140(1):91-100.  
55  
56  
57 21. Wang H, Lee IS, Braun C, et al. Effect of Probiotics on Central Nervous  
58  
59 System Functions in Animals and Humans: A Systematic Review. J  
60

- 1  
2  
3 Neurogastroenterol Motil. 2016 Oct 30;22(4):589-605.  
4  
5  
6 22. Lener MS, Niciu MJ, Ballard ED, et al. Glutamate and Gamma-Aminobutyric  
7 Acid Systems in the Pathophysiology of Major Depression and Antidepressant  
8 Response to Ketamine. *Biol Psychiatry*. 2017 May 15;81(10):886-897.  
9  
10  
11 23. Al Omran Y, Aziz Q. Functional brain imaging in gastroenterology: to new  
12 beginnings. *Nat Rev Gastroenterol Hepatol*. 2014 Sep;11(9):565-76.  
13  
14  
15 24. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product  
16 with probiotic modulates brain activity. *Gastroenterology*. 2013 Jun;144(7):1394-401,  
17 1401.e1-4.  
18  
19  
20 25. Agostini A, Filippini N, Cevolani D, et al. Brain functional changes in patients  
21 with ulcerative colitis: a functional magnetic resonance imaging study on emotional  
22 processing. *Inflamm Bowel Dis*. 2011 Aug;17(8):1769-77.  
23  
24  
25 26. Smitha KA, Akhil Raja K, Arun KM, et al. Resting state fMRI: A review on  
26 methods in resting state connectivity analysis and resting state networks. *Neuroradiol*  
27 *J*. 2017 Aug;30(4):305-317.  
28  
29  
30 27. Bagga D, Reichert JL, Koschutnig K, et al. Probiotics drive gut microbiome  
31 triggering emotional brain signatures. *Gut Microbes*. 2018 Nov 2;9(6):486-496.  
32  
33  
34 28. Tillisch K, Mayer EA, Gupta A, et al. Brain Structure and Response to Emotional  
35 Stimuli as Related to Gut Microbial Profiles in Healthy Women. *Psychosom Med*. 2017  
36 Oct;79(8):905-913.  
37  
38  
39 29. Bagga D, Aigner CS, Reichert JL, et al. Influence of 4-week multi-strain probiotic  
40 administration on resting-state functional connectivity in healthy volunteers. *Eur J*  
41 *Nutr*. 2019 Aug;58(5):1821-1827.  
42  
43  
44 30. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool  
45 for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. Published 2011  
46 Oct 18.  
47  
48  
49 31. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series  
50 of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol*. 2011;64(4):380–  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 382.  
4

5  
6 32. Lu Liu, Xi Xiu NI, TIAN TIAN, et al. Effect of regulating gut microbiota using  
7 probiotics on brain activity: protocol of a systematic review. PROSPERO 2019  
8 CRD42019145114. Available: [http://www.crd.york.ac.uk/PROSPERO/display\\_record.](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42019145114)  
9  
10  
11  
12 asp?ID=CRD42019145114  
13

14 33. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic  
15 review and meta- analysis protocols (PRISMA- P) 2015: elaboration and explanation.  
16 BMJ 2015;350:g7647.  
17

18 34. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic  
19 review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.  
20  
21

22 35. Vos, T., Allen, C., Arora, M., et al. (2016). Global, regional, and national  
23 incidence, prevalence, and years lived with disability for 310 diseases and  
24 injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study  
25 2015. The Lancet, 388  
26  
27  
28  
29  
30  
31  
32 (10053), 1545–1602.  
33

34 36. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke,  
35 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.  
36  
37  
38  
39  
40  
41  
42 Lancet Neurol 2019;18:439–58.

43 37. GBD 2016 Dementia Collaborators. Global, regional, and national burden of  
44 Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the  
45 Global Burden of Disease Study 2016. Lancet Neurol 2019;18:88–106.  
46

47 38. GBD 2016 Epilepsy Collaborators. Global, regional, and national burden of  
48 epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study  
49 2016. Lancet Neurol 2019;18:357–75.  
50  
51

52 39. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national  
53 burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global  
54 Burden of Disease Study 2016. Lancet Neurol 2018;17:939–53.  
55  
56  
57

58 40. GBD 2016 Neurology Collaborators. Global, regional, and national burden of  
59  
60

1  
2  
3 neurological disorders, 1990–2016: a systematic analysis for the Global Burden of  
4 Disease Study 2016. *Lancet Neurol* 2019;18:459–80.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Search strategy for the Pubmed database is as follows,and filters in article types,publiation dates and species,we chose clinical trails,10years and humans respectively.

Table 1 Search strategy for the Pubmed database

1.probiotics. Mesh.	27.magnetic resonance imaging. Mesh.
2.culturelle. ti, ab	28.fMRI. ti, ab
3.bifidobacteria. ti, ab	29.MRI. ti, ab
4.lactobailli. ti, ab	30.MR. ti, ab
5.escherichia coli. ti, ab	31.functional magnetic resonance imaging. ti, ab
6.yogurt. ti, ab	32.NMR Imaging. ti, ab
7.yeast. ti, ab	33.neuroimaging. ti, ab
8.saccharomyces. ti, ab	34.brian activity. ti, ab
9.bacillus. ti, ab	35.MR tomography. ti, ab
10.enterococcus. ti, ab	36.independent component analysis. ti, ab
11.streptococcus. ti, ab	37. functional network connectivity. ti, ab
12.fermented milk. ti, ab	38.amplitude of low frequency fluctuations. ti, ab
13.sour milk. ti, ab	39.regional homogeneity. ti, ab
14. 1 or 2-13	40.functional connectivity. ti, ab
15.gastrointestinal microbiome. Mesh.	41.central. ti, ab
16.gut microbiota. ti, ab	42.brain. ti, ab
17.gut microbiome. ti, ab	43.neuro. ti, ab
18.gut microflora. ti, ab	44.ALFF. ti, ab
19.intestinal microflora. ti, ab	45.FALFF. ti, ab
20.intestinal bacteria. ti, ab	46.ReHo. ti, ab
21.intestinal microbiome. ti, ab	47.ROI. ti, ab
22.microbiome. ti, ab	48.ICA. ti, ab
23.microbiota. ti, ab	49.FC. ti, ab
24.flora. ti, ab	50. 27 or 28-49
25.bacteria. ti, ab	51. 14 or 26
26. 15 or 16-25	52.(Final search) 50 and 51